Safety and Activity of the Immune Modulator HE2000 on the Incidence of Tuberculosis and Other Opportunistic Infections in AIDS Patients

ABSTRACT Twenty-five AIDS patients were treated with HE2000, a synthetic adrenal hormone. The drug was well tolerated and safe and reduced both the incidence of tuberculosis coinfection by 42.2% (P < 0.05) and the cumulative incidence of opportunistic infections (P < 0.05). These results warrant further clinical investigation of HE2000.

[1]  G. Rook,et al.  16alpha-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis. , 2005, The Journal of infectious diseases.

[2]  D. Freilich,et al.  16alpha-bromoepiandrosterone, a dehydroepiandrosterone (DHEA) analogue, inhibits Plasmodium falciparum and Plasmodium berghei growth. , 2000, The American journal of tropical medicine and hygiene.

[3]  Wayne B. Nelson,et al.  Recurrent Events Data Analysis for Product Repairs, Disease Recurrences, and Other Applications , 2002 .

[4]  P. Fitzgerald-Bocarsly,et al.  Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. , 2001, Clinical immunology.

[5]  A. Garsd,et al.  Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000). , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  William Q. Meeker,et al.  Recurrent Events Data Analysis for Product Repairs, Disease Recurrences, and Other Applications , 2003, Technometrics.

[7]  Zhiliang Ying,et al.  Semiparametric regression for the mean and rate functions of recurrent events , 2000 .

[8]  P. Arese,et al.  16α-Bromoepiandrosterone, an Antimalarial Analogue of the Hormone Dehydroepiandrosterone, Enhances Phagocytosis of Ring Stage Parasitized Erythrocytes: a Novel Mechanism for Antimalarial Activity , 2002, Antimicrobial Agents and Chemotherapy.

[9]  C. Rinaldo,et al.  Selective decrease in human immunodeficiency virus type 1 (HIV-1)-induced alpha interferon production by peripheral blood mononuclear cells during HIV-1 infection , 1995, Clinical and diagnostic laboratory immunology.

[10]  L. Pedneault,et al.  Intra-Assay Performance Characteristics of Five Assays for Quantification of Human Immunodeficiency Virus Type 1 RNA in Plasma , 1998, Journal of Clinical Microbiology.

[11]  P. Ghys,et al.  © Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2004 , 2004 .

[12]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[13]  N. Kadowaki,et al.  The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.

[14]  S. Krudsood,et al.  Reduction of parasite levels in patients with uncomplicated malaria by treatment with HE2000. , 2007, The American journal of tropical medicine and hygiene.

[15]  N. Pedersen,et al.  16alpha-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression. , 2003, Veterinary immunology and immunopathology.

[16]  F. Siegal,et al.  Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity. , 1986, The Journal of clinical investigation.

[17]  F. Gheyas,et al.  Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. , 2001, Blood.